Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
Cambio hacia las ganancias
El rendimiento de la empresa ha pasado a ser rentable. Sus ingresos netos anuales más recientes han sido de USD.
Sobrevalorada
El PE más reciente de la empresa es 31.89, en un rango percentil alto de 3 años.
Venta institucional
Las tenencias institucionales más recientes son 162.52M acciones, lo que supone una reducción del 8.64% con respecto al trimestre anterior.
En posesión de Catherine Wood
El inversor estrella Catherine Wood posee 927.08K acciones de este valor.
Mayor actividad del mercado
La empresa está generando mayor interés entre los inversores, con una relación de rotación de 20 días del 0.09.